GROWERIQ
13.9.2022 14:06:45 CEST | Business Wire | Press release
GrowerIQ, the leading cannabis enterprise resource planning (ERP) platform, today announced it recently closed an oversubscribed $3 million CAD ($2.3 million USD) seed round. The round was co-led by Golden Section and MaRS IAF, with participation from LAGO, Delbridge, GTM Fund and Gaingels.
Non-cannabis ERP systems don't work for cannabis production, so producers are stuck using Excel or outdated software that do not talk to each other. This makes it hard to gather data for compliance reporting or analysis.
GrowerIQ was founded to help cannabis companies simplify operations, stay compliant and leverage data to improve their bottom line. The company's ERP includes modules for cultivation, manufacturing, warehouse, CRM, orders and quality management.
Launched in 2020, GrowerIQ has become the go-to solution for cannabis businesses of all sizes, with customers in more than a dozen countries. The company has been credited with driving significant operational efficiencies and savings for its customers.
"This funding allows us to heavily invest in our tech and continue building the most comprehensive cannabis management platform on the market," said GrowerIQ founder and CEO, Andrew Wilson. "We're thrilled to have the support of such experienced investors as we grow our business and help more cannabis companies streamline their operations."
"We invest in founders who have subject matter expertise and vision," said Golden Section Executive Director, Andrew Smith. "The company's leadership certainly meets those criteria, as it seeks to solve a major pain point in an emerging industry that will help businesses be more efficient and compliant on a global scale. The impressive customer base and track record of success, coupled with a focus on capital efficiency and product quality, make this a natural fit for our portfolio. We're excited to partner with GrowerIQ as they scale their business and continue innovating."
The MaRS IAF team said, "The GrowerIQ team impressed us with their deep understanding of the customers and market, and how their needs informed the product development. Throughout the process the team continued to execute on their go to market strategy and consistently drive strong growth. It was quite clear that GrowerIQ was solving a very meaningful problem for their customers. It's been great to work with the team and we look forward to being part of the growth journey."
About GrowerIQ
GrowerIQ is the operational backbone ERP that unites the fragmented systems required by cannabis production facilities around the world. The company now powers facilities in more than a dozen countries, and four languages – enabling true seed-to-sale traceability. For information, visit www.groweriq.com.
About Golden Section
Golden Section is a Houston-based venture capital fund started by experienced business software founders that invests in early-stage B2B SaaS companies. The fund aims to partner with founders, pre-seed to post sale, through a differentiated offering to reduce confusion and chaos, augment team expertise, with an emphasis on capital efficiency, balance, and revenue growth. Our mission is to journey together with founders towards their meaningful exit. www.goldensection.com
About MaRS Investment Accelerator Fund
MaRS Investment Accelerator Fund (IAF) is a leading seed stage fund investing in high-potential IT, health, and cleantech companies. IAF has, over a 10-year history, partnered with 150+ founders building world-class companies. www.marsiaf.com
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220913005435/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Consortium Led by Axelspace Selected for Japan’s Space Strategy Fund Project “Technology to Enhance Capability of Next Generation Earth Observation Satellites”30.3.2026 01:35:00 CEST | Press release
~ Creating Climate Solutions and New Market Opportunities through Source-Specific CO2 Emission and Uptake Monitoring via Satellite Constellation and Aircraft ~ Axelspace Corporation, Meisei Electric Co., Ltd., ANA HOLDINGS INC., and JIJ Inc. are pleased to announce that their jointly proposed technology development project has been selected for Japan Aerospace Exploration Agency (JAXA)’s Space Strategy Fund under the theme “Technology to Enhance Capability of Next Generation Earth Observation Satellites.” This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260323044518/en/ Conceptual Diagram of the project. Under this Space Strategy Fund initiative, spectrometers will be newly developed and demonstrated in orbit. In the future, the project envisions the establishment of a satellite constellation capable of observations at different times of the day. Project Summary (Planned) Technology Development Theme: Technology to Enhance Cap
Incyte Announces New Positive 54-Week Late-Breaking Data for Povorcitinib in Hidradenitis Suppurativa at the 2026 American Academy of Dermatology (AAD) Annual Meeting28.3.2026 20:00:00 CET | Press release
Phase 3 data from the STOP-HS program demonstrate povorcitinib’s substantial and durable clinical efficacy through Week 54 in patients with moderate to severe hidradenitis suppurativa (HS). Through Week 54, clinically meaningful and durable responses were observed across all groups in both STOP-HS1 and STOP-HS2, with up to 71.4% of patients achieving HiSCR50. Improvements in clinical responses across high stringent thresholds were observed, with up to 57% of participants achieving HiSCR75 and up to 29% of participants achieving HiSCR100. Povorcitinib treatment led to consistent reductions across key inflammatory lesion types, with full resolution (ANdT=0) achieved in up to 20% of patients. Additionally, clinically meaningful improvements in quality-of-life measures, including skin pain and fatigue, were observed at Week 54. The overall safety profile of povorcitinib through 54 weeks is consistent with previously reported data, and both doses were well tolerated. Incyte (Nasdaq:INCY) to
Takeda’s Zasocitinib Delivered Rapid and Durable Skin Clearance in a Convenient Once-Daily Pill, Affirming Promise to Reshape Psoriasis Care28.3.2026 20:00:00 CET | Press release
About 70% of patients treated with zasocitinib achieved clear or almost clear skin (sPGA 0/1) at week 16 in Phase 3 plaque psoriasis studies A significantly greater PASI 75 response rate versus placebo was observed as early as week 4 Safety profile consistent with Phase 2b studies with no new safety signals identified Takeda(TSE:4502/NYSE:TAK)today announced new data from the two pivotal Phase 3studies of zasocitinib (TAK-279), a next-generation, highly selective oral tyrosine kinase 2 (TYK2) inhibitor, in adults with moderate-to-severe plaque psoriasis (PsO).1 Presented as a late-breaking abstract at the 2026 American Academy of Dermatology (AAD) Annual Meeting, these data show that convenient once-daily oral zasocitinib demonstrated rapid and durable skin clearance with a safety profile consistent with Phase 2b studies.1,2 “Our goal in psoriasis treatment is clear or almost clear skin, and previously this has been achieved primarily with injectable therapies,” said Melinda Gooderham,
AAD 2026: Late-Breaking Nemolizumab Data Demonstrate Clinically Meaningful Benefits for Children Aged 2 to 11 With Moderate-to-Severe Atopic Dermatitis28.3.2026 16:00:00 CET | Press release
Pharmacokinetics, safety and efficacy clinical study data show that nemolizumab achieved clinically meaningful reductions in skin lesions and itch through Week 16, which were sustained up to a year in children aged 2 to 11 with moderate-to-severe atopic dermatitis1 These findings reinforce the previously established safety and efficacy of nemolizumab in adults and adolescents with moderate-to-severe atopic dermatitis, for which it is approved by multiple global regulatory authorities2,3 Up to 25% of children are affected by atopic dermatitis, and currently there are limited approved treatment options for children living with moderate-to-severe atopic dermatitis4,5 Galderma (SIX: GALD) today announced new phase II data showing that nemolizumab was well tolerated and effective in children (aged 2 to 11 years) with moderate-to-severe atopic dermatitis, with a clinically meaningful and sustained reduction in skin lesions and itch for up to a year.1 Results will be presented in a late-break
Angelalign Technology (6699.HK)Releases 2025 Results: Passion for Clinical Excellence Drives Worldwide Growth27.3.2026 20:56:00 CET | Press release
Angelalign Technology Inc. (6699.HK) (“Angel” or the “Company”) released its financial results for fiscal year 2025. During the reporting period, the Company continued to do well in both the global and China markets. Total case volume was 532,400, which increased 48.1%, revenue was USD 370.3 million, which increased 37.8%, and adjusted net profit was USD 43.8 million, which increased 63.0%. The results were driven by Angel’s passion for clinical excellence and its open and inclusive culture that empowers talented people to work together to meet customer needs, the Company said. Fox Hu, CEO of Angel, stated: “The clear aligner industry is complex and multidisciplinary. It requires top-tier technical and operational talent along with seamless collaboration among professionals from diverse geographies. Angel’s open and inclusive culture attracts professionals who share a passion for clinical excellence and a dedication to bringing outstanding products and services to customers. This melti
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom